View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 8, 2021

Keen Eye introduces AI-powered platform to support clinical trials

The platform will help in accelerating clinical trials with deep learning-based image analysis.

French health tech company Keen Eye has launched a new artificial intelligence (AI) web-based platform to support organisations conducting clinical trials.

The computational pathology platform is Good Clinical Laboratory Practices (GCLP) compliant and will help in expediting clinical trials with deep learning-based image analysis. It will allow every actor in pathology to run digital image analysis efficiently.

The platform will address the safety of clinical trial subjects and ensure the integrity of study data. An audit trail also captures every action performed on the platform.

Keen Eye founder and CEO Sylvain Berlemont said: “It provides a quantum leap in performance while contributing to regulatory compliance, hence paving the way for better standards in clinical image analysis.

“We are proud to have developed the solution every pharma and CRO has been waiting for.”

Institut Gustave Roussy, France, former head of pathology Dr Jacques Bosq said: “As pathologists, we always put patients’ interests first. Keen Eye’s expertise in digital tissue analysis has proven to be a really effective solution.

“With this innovative GCLP-compliant platform, pathologists will be able to perform biomarker detection and quantification in clinical study protocols in a reliable, standardised and efficient manner.”

The company will demonstrate the platform’s capabilities during Oxford Global’s ‘Biomarkers UK’ event in November 2021.

Established in 2015, Keen Eye works to advance the use of AI for the benefit of biologists, pathologists and patients. The company also aims to support the development of new therapies with improved analytics.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy